直肠癌术中局部应用5-FU缓释剂的临床研究  

Clinical Study on Chemotherapy for Rectal Cancer with 5-Fluorouracil Sustained Release Agent During Operation

作　　者：白景舒[1] 张积书[1] 白晓刚[1] 

机构地区：[1]大连大学附属新华医院肛肠外科,辽宁大连116021

出　　处：《中国肛肠病杂志》2008年第12期16-17,共2页Chinese Journal of Coloproctology

摘　　要：为探讨直肠癌患者术中腹腔放置5-FU缓释剂化疗的用药剂量、不良反应及其对吻合口的影响，将28例直肠癌患者随机分成两组，每组14例，将不同剂量的5-FU缓释剂（500mg、800mg）在术中植入可能有淋巴结亚临床转移的区域。观察患者术后2周的不良反应，了解剂量和安全性的关系。结果显示，术后2周连续观察患者，未发现术中使用5-FU缓释剂对手术恢复有不良影响，也无严重的全身不良反应和术后并发症，两组的不良反应无显著差异。结果表明，直肠癌术中应用5-FU缓释剂对直肠癌的化疗具有良好的安全性。The objective of this study was to evaluate the effect of a neoadjunvant chemotherapy with 5-fluorouracil sustained release agent for implant（5 FU SRAI） implanted in abdominal cavity of the patients as rectal cancer during operation,28 patients diagnosed as rectal cancer were randomly divided into the lowdose group（500mg） （ n =14） and the high-dose group（800mg）（ n= 14）. 5-FU SRAI of various dose were implanted into the position being likely lymphatic metastasis subclinically during operation. Adverse reaction was observed during the 2 weeks postoperatively in order to evaluate the relation between dose and se curity. During the observation of 2 weeks, 5-FU SRAI had not any side effect on the recovery of postoperative patients. No adverse reaction and postoperative complications were found in all the patients. There were not differences significantly among adverse reactions in various dose groups. It is revealed that the treatment of 5-FU SRAI implanted in abdominal cavity of rectal cancer patients during operation is safe.

关 键 词：直肠肿瘤 5-FU 化学疗法 

分 类 号：R735.37[医药卫生—肿瘤] R781.4[医药卫生—临床医学]